Citations

Clear

815 citation(s) found for "Tang, Yu".

Aging-dependent dysregulation of EXOSC2 is maintained in cancer as a dependency
Skamagki, Maria , Hacisuleyman, Ezgi , Galleti, Giuseppe, Vinagolu, Rajasekhar, Cha, HyoKyeong, Ata, Deniz, Kim, Jong-Jin , Weiskittel, Taylor M. , Diop, Mame, Aung, Thiri, Latto, Michael Del , Kim, Amanda S., Li, Zhuoning , Zhao, Rui , Hendrickson, Ronald C. , Bott, Matthew J. , Hu, Li , Romesser, Paul B , Smith, J Joshua , Giannakakou, Paraskevi , Zhang, Cheng, Wu, Chao , Cha, HyoKyeong, Kim, Jongjin, Diop, Mame, Aung, Thiri, Miele, Matthew M. , Tang, Laura H. , Hendrickson, Ronald C. , Romesser, Paul B. , Smith, J. Joshua , Darnell, Robert B. , Li, Hu, Kim, Kitai

Mayo Clinic

No container title available | April 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.04.647279 | PMID 40236131 Get It

Abstract Reprogramming of aged donor tissue cells into induced pluripotent stem cells (A-iPSC) preserved the epigenetic memory of aged-donor tissue, defined as genomic instability and poor tissue differentiation in our previous study. The unbalanced expression of RNA exosome subunits affects the RNA degradation complex function and is associated with geriatric diseases including premature aging and cancer progression. We hypothesized that the age-dependent progressive subtle dysregulation of EXOSC2 (exosome component 2) causes the aging traits (abnormal cell cycle and poor tissue differentiation). We used embryonic stem cells as a tool to study EXOSC2 function as the aging trait epigenetic memory determined in A-iPSC because these aging traits could not be studied in senesced aged cells or immortalized cancer cells. We found that the regulatory subunit of PP2A phosphatase, PPP2R5E, is a key target of EXOSC2 and this regulation is preserved in stem cells and cancer.
Proton dose calculation with transformer: Transforming spot map to dose
Tang, Xueyan , Tseung, H. Wan Chan, Johnson, Jed E., Moseley, D.J., Tseung, Hok Wan Chan, Moseley, Doug J, Qian, Jing , Pepin, Mark D., Routman, David M. , Qian, Jing

Mayo Clinic

Medical Physics | March 31, 2025 | Volume: 52 | Issue: 6 | Pages: 4941-4952

10.1002/mp.17794 | PMID 40156258 Get It

Abstract Background Conventional proton dose calculation methods are either time‐ and resource‐intensive, like Monte Carlo (MC) simulations, or they sacrifice accuracy, as seen with analytical methods. This trade‐off between computational efficiency and accuracy highlights the need for improved dose calculation approaches in clinical settings. Purpose This study aims to develop a deep‐learning‐based model that calculates dose‐to‐water ( D W ) and dose‐to‐medium ( D M ) using patient anatomy and proton spot map (PSM), achieving approaching MC‐level accuracy with significantly reduced computation time. Additionally, the study seeks to generalize the model to different treatment sites using transfer learning. Methods A SwinUNetr model was developed using 259 four‐field prostate proton stereotactic body radiation therapy (SBRT) plans to calculate patient‐specific D W and D M distributions from CT and projected PSM (PPSM). The PPSM was created by projecting PSM into the CT scans using spot coordinates, stopping power ratio, beam divergence, and water‐equivalent thickness. Fine‐tuning was then performed for the central nervous system (CNS) site using 84 CNS plans. The model's accuracy was evaluated against MC simulation benchmarks using mean absolute error (MAE), gamma analysis (2% local dose difference, 2‐mm distance‐to‐agreement, 10% low dose threshold), and relevant clinical indices on the test dataset. Results The trained model achieved a single‐field dose calculation time of 0.07 s on a Nvidia‐A100 GPU, over 100 times faster than MC simulators. For the prostate site, the best‐performing model showed an average MAE of 0.26 ± 0.17 Gy and a gamma index of 92.2% ± 3.1% in dose regions above 10% of the maximum dose for D W calculations, and an MAE of 0.30 ± 0.19 Gy with a gamma index of 89.7% ± 3.9% for D M calculations. After transfer learning for CNS plans, the model achieved an MAE of 0.49 ± 0.24 Gy and a gamma index of 90.1% ± 2.7% for D W computations, and an MAE of 0.47 ± 0.25 Gy with a gamma index of 85.4% ± 7.1% for D M computations. Conclusions The SwinUNetr model provides an efficient and accurate method for computing dose distributions in proton therapy. It also opens the possibility of reverse‐engineering PSM from D W , potentially speeding up treatment planning while maintaining accuracy.
Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions
Tang, Justin , Karbhari, Nishika , Campian, Jian , Karbhari, Nishika

Mayo Clinic

Cells | March 26, 2025 | Volume: 14 | Issue: 7 | Pages: 494

10.3390/cells14070494 | PMID 40214448 Get It

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid growth, invasive infiltration into surrounding brain tissue, and resistance to conventional therapies. Despite advancements in surgery, radiotherapy, and chemotherapy, median survival remains approximately 15 months, underscoring the urgent need for innovative treatments. Key considerations informing treatment development include oncogenic genetic and epigenetic alterations that may dually serve as therapeutic targets and facilitate treatment resistance. Various immunotherapeutic strategies have been explored and continue to be refined for their anti-tumor potential. Technical aspects of drug delivery and blood–brain barrier (BBB) penetration have been addressed through novel vehicles and techniques including the incorporation of nanotechnology. Molecular profiling has emerged as an important tool to individualize treatment where applicable, and to identify patient populations with the most drug sensitivity. The goal of this review is to describe the spectrum of potential GBM therapeutic targets, and to provide an overview of key trial outcomes. Altogether, the progress of clinical and preclinical work must be critically evaluated in order to develop therapies for GBM with the strongest therapeutic efficacy.
Controversy in Hypertension: Pro-Side of the Argument Using Artificial Intelligence for Hypertension Diagnosis and Management
Armoundas, Antonis A. , Ahmad, Faraz S. , Attia, Zachi I. , Doudesis, Dimitrios , Khera, Rohan , Kyriakoulis, Konstantinos G. , Stergiou, George S. , Tang, W.H. Wilson , Tang, W H Wilson , Attia, Zachi I , Ahmad, Faraz , Khera, Rohan , Stergiou, George , Armoundas, Antonis A

Mayo Clinic

Hypertension | March 17, 2025 | Volume: 82 | Issue: 6 | Pages: 929-944

10.1161/hypertensionaha.124.22349 | PMID 40091745 Get It

Hypertension presents the largest modifiable public health challenge due to its high prevalence, its intimate relationship to cardiovascular diseases, and its complex pathogenesis and pathophysiology. Low awareness of blood pressure elevation and suboptimal hypertension diagnosis serve as the major hurdles in effective hypertension management. Advances in artificial intelligence in hypertension have permitted the integrative analysis of large data sets including omics, clinical (with novel sensor and wearable technologies), health-related, social, behavioral, and environmental sources, and hold transformative potential in achieving large-scale, data-driven approaches toward personalized diagnosis, treatment, and long-term management. However, although the emerging artificial intelligence science may advance the concept of precision hypertension in discovery, drug targeting and development, patient care, and management, its clinical adoption at scale today is lacking. Recognizing that clinical implementation of artificial intelligence–based solutions need evidence generation, this opinion statement examines a clinician-centric perspective of the state-of-art in using artificial intelligence in the management of hypertension and puts forward recommendations toward equitable precision hypertension care.
Assessment of Left‐Sided Hemodynamics With Exercise in Patients With Continuous Flow Left Ventricular Assist Device Support
Inglis, Sara S. , Schettle, Sarah , Villavicencio, Mauricio A. , Spencer, Philip J. , Stulak, John M., Kushwaha, Sudhir S. , Behfar, Atta, Rosenbaum, Andrew , Schettle, Sarah D , Rosenbaum, Andrew N , Inglis, Sara S , Tang, Paul C. , Behfar, Atta

Mayo Clinic

Artificial Organs | March 13, 2025 | Volume: 49 | Issue: 9 | Pages: 1462-1469

10.1111/aor.14995 | PMID 40078038 Get It

ABSTRACT Background Addition of left heart catheterization (LHC) to exercise protocols allows for a unique focus on parameters of systolic and diastolic responses to increased activity in patients with left ventricular assist device (LVAD) support. Methods A retrospective review was conducted of all consecutive adult patients who underwent LHC with exercise for any indication from June 2017 to June 2023. For all patients, the relationship between exercise and parameters of LV systolic and diastolic response was assessed. Patients were divided into two cohorts based on the indication for testing: hemodynamic optimization (Optim, n = 5) or weaning consideration (Wean, n = 3). Results Eight patients (88% male, median age 57 years (IQR 44, 65)) were included. LVEF was 45% (IQR 45, 56) in Wean and 25% (IQR 20, 42) in Optim. LV systolic work index (LVSWI) increased more rapidly over levels of exercise in Wean vs. Optim (slope 46.3 vs. −0.625; p = 0.044) and LVSWI rose more quickly at lower levels of LV end diastolic pressure (LVEDP) in Wean vs. Optim (slope 219.5 vs. −2.008; p = 0.0026). Pulse power index was higher in Wean patients at baseline (0.046 (IQR 0.04, 0.07) vs. 0.016 (IQR 0.001, 0.04); p = 0.14) and peak exercise (0.12 (IQR 0.12, 0.12) vs. 0.06 (IQR 0.03, 0.1); p = 0.29). Conclusions Patients with favorable remodeling on LVAD support have significantly improved LV systolic and diastolic responses to exercise and a trend of higher systemic pulsatility. Improving our understanding of LV‐LVAD interactions with activity may aid in future efforts to improve exercise tolerance through speed modulation.
Characterization of transcriptomic changes in the neurovascular unit of Alzheimiers transgenic mouse models using digital spatial profiling
Salian, Vrishali S. , Lowe, Val J. , Salian, Vrishali , Thompson, Kevin J. , Tang, Xiaojia , Kalari, Krishna R. , Kandimalla, Karunya K.

Mayo Clinic

No container title available | March 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.03.640886 | PMID 40492192 Get It

Abstract Alzheimer’s disease (AD) affects 40 million individuals globally and is characterized by the accumulation of amyloid-beta (Aβ) proteins, which aggregate and form plaques. BBB dysfunction drives AD cerebrovascular pathology and BBB integrity is maintained by neurovascular unit (NVU). Specifically, within the NVU, the cerebral endothelial cells maintain vascular homeostasis. In this study, we isolated endothelial-enriched regions of interest (ROIs) using the Nanostring GeoMx digital spatial profiler and employed a deconvolution model to evaluate transcriptomic changes. We observed dysregulation of cellular signaling potentially disrupting the APP+ BBB integrity. Analysis of ligand-receptor pairings that are the foundation of the NVU intercellular signaling indicated that the endothelial vasculature completes a feedback loop with the NVU to the regulating astroctyes. Further, we identified potentially antagonistic signaling roles for opioid receptor species that should be further investigated for potential therapeutic targets. Graphical Abstract
SPINK1-COL18A1 Crosstalk Shapes Epigenome and Drives Cancer Stemness in Pancreatic Ductal Adenocarcinoma
García-Milian, Rolando , Tang, Haoyu , Iacobuzio-Donahue, Christine A , Sailo, Bethsebie, Shang, Xingbo, Hossan, Md Shahadat , Kratz, Jeremy D. , Das, Paromita , Chhoda, Ankit , Aldo, Paulomi, Liu, He , Robert, Marie E. , Doucette, Saryn , Paris, Timothy J., Kunstman, John W. , Pappou, Emmanouil, Wood, Laura D. , Iacobuzio–Donahue, Christine A. , Wolfgang, Christopher L. , Mazzetto, Mariateresa , He, Linda, Pfaff, Marie, Hoggard, Timothy , Sharma, Anup, Levchenko, Andre , Ahuja, Nita

Mayo Clinic

No container title available | March 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.03.641251 | PMID 40093187 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer with an increasing incidence and extremely dismal prognosis. Discovery and mechanistic understanding of the genetic and epigenetic drivers of PDAC is therefore of critical importance. Here, we uncover serine protease inhibitor Kazal type 1 (SPINK1) as a putative determinant of clinical progression and demonstrate that it can have a non-canonical function as a regulator of epigenomic states of PDAC cells and associated extensive changes in gene expression. We show that SPINK1 expression, which varies in PDAC, is associated with key aggressive phenotypic cancer states and is correlated with the expression of stemness markers both in vitro and in patient samples. Mechanistically, our results strongly suggest that SPINK1 acts through a new signaling axis, by interacting with COL18A1 in the Golgi apparatus, promoting endostatin release and eventually inducing extensive histone H3 modifications. These results reveal a new function of SPINK1 in PDAC and suggest a potential therapeutic route to combat PDAC aggressiveness by targeting the SPINK1-COL18A1-endostatin signaling.